Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ALNY > SEC Filings for ALNY > Form 8-K on 27-Feb-2014All Recent SEC Filings

Show all filings for ALNYLAM PHARMACEUTICALS, INC.

Form 8-K for ALNYLAM PHARMACEUTICALS, INC.


27-Feb-2014

Entry into a Material Definitive Agreement, Material Modification t


Item 1.01. Entry Into a Material Definitive Agreement.

On February 27, 2014, as a condition to the closing of a stock purchase agreement by and between Alnylam Pharmaceuticals, Inc. (the "Company") and Genzyme Corporation ("Genzyme"), the Company entered into an Investor Agreement with Genzyme (the "Investor Agreement"). A description of the terms and conditions of the Investor Agreement that are material to the Company is set forth in the Current Report on Form 8-K filed by the Company on January 13, 2014 under the heading "Equity Placement" in Item 1.01 of such Current Report on Form 8-K, which description is incorporated herein by reference.



Item 3.03. Material Modification to Rights of Security Holders.

On February 27, 2014, contemporaneously with the execution of the Investor Agreement, the Company entered into a First Amendment to Rights Agreement (the "Amendment") with Computershare Trust Company, N.A., as rights agent, to amend the terms of the Rights Agreement dated as of July 13, 2005 between the Company and Computershare Trust Company, N.A., f/k/a EquiServe Trust Company, N.A. (the "Rights Agreement"). The Amendment permits Genzyme to exercise its rights under the Investor Agreement (the "Exemption"). Such rights include, in general, Genzyme's ability to acquire up to 30% of the Company's outstanding shares of common stock during the standstill term set forth in the Investor Agreement, and Genzyme's right to participate proportionally in future issuances of the Company's common stock to maintain its then-current ownership percentage of the Company's common stock. With an exception relating to Genzyme's exercise of any continuing anti-dilution rights, the Exemption terminates if, following the standstill term under the Investor Agreement, Genzyme and its affiliates collectively beneficially own less than 20% of the outstanding shares of the Company's common stock.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 4.1 hereto and is incorporated herein by reference.



Item 7.01. Regulation FD Disclosure.

On February 27, 2014, the Company issued a press release, a copy of which is being furnished as Exhibit 99.1 to this Report on Form 8-K, announcing that, following the termination of the Hart-Scott-Rodino waiting period, in consideration for the rights granted to Genzyme under the parties' alliance, Genzyme purchased 8,766,338 shares of newly issued Company' common stock, representing an approximately 12% ownership position, and paid the Company $700.0 million in aggregate cash consideration, pursuant to its previously announced agreement. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing




Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
  No.                                       Document

 4.1         First Amendment to Rights Agreement, dated as of February 27, 2014 by
             and between the Company and Computershare Trust Company, N.A., as
             rights agent

99.1         Press Release issued by the Company, dated February 27, 2014


  Add ALNY to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ALNY - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.